Issued and outstanding: 42,893,928 (2007
- 40,305,028)
Subscriptions received -- 9,170
Additional paid in capital 41,629,506 32,109,997
Accumulated other comprehensive income 3,773,224 1,956,456
Dedicated reserves 5,549,684 2,999,396
Accumulated deficit (1,281,534) (7,111,469)
Total stockholders' equity 49,713,775 30,003,855
Total liabilities and stockholders'
Equity $ 83,203,222 $ 57,447,962
The accompanying notes are an integral part of these consolidated
financial statements.
SINOVAC BIOTECH LTD.
Consolidated Statements of Income and Comprehensive Income
Three Months and Twelve months Ended December 31, 2008 and 2007
(Unaudited)
(Expressed in U.S. Dollars)
Three months ended Twelve months ended
December 31, December 31,
2008 2007 2008 2007
Sales $12,359,803 $9,201,946 $46,496,904 $33,541,187
Cost of sales - (exclusive
of depreciation of
land-use rights and
amortization of licenses
and permits of $104,000
[2007 - $96,296] for three
months and $411,065
[2007- 376,184] for
twelve months) 4,615,674 2,915,135 9,936,341 6,502,328
Gross profit 7,744,129 6,286,811 36,560,563 27,038,859
Selling, general and
administrative expenses 4,054,222 2,472,518 17,462,674 11,958,498
Research and development
expenses - net of
$162,064(2007- $401,935)
for three months and
$310,222 (2007- $843,910)
for twelve months in
government research
grants
'/>"/>SOURCE Sinovac Biotech Ltd. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Related biology technology :1.
Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results2.
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2008 Financial Results3.
Sinovac Biotech Co. Ltd., Sinovacs Beijing Subsidiary, Obtains High-Tech Enterprise Status4.
Sinovac Receives GMP Certification for its New Filling and Packaging Production Facility5.
Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine6.
Sinovac Releases Statement on Healive Vaccine Suspension7.
Sinovac Reports Third Quarter 2008 Unaudited Financial Results8.
Sinovac Named to Deloitte Technology Fast 50 China9.
Sinovac to Participate in Two Upcoming Investor Conferences10.
Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating11.
Sinovac Biotech Holds 2007 Annual General Meeting